The 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications was held from Monday, November 14 to Friday, November 18, 2005 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The level of excitement surrounding targeted therapy and the high caliber of the science presented attracted the world’s leaders in the development of new cancer therapeutics. In 2005, the beginning of an effort to sequence cancer genomes, a more systematic approach to biomarker identification based on proteomics, and advances in functional imaging heralded the future of drug discovery.
The Scientific Committee, led by Co-Chairpersons Robert B. Diasio, James H. Doroshow, and Pierre Fumoleau, along with 47 experts from throughout the U.S. and Europe developed a comprehensive schedule of sessions that facilitated the translation of basic science into new therapeutic strategies, and made a major contribution to moving the field forward.
The conference provided a forum for discussion of the latest findings and new directions in research in drug development, cancer therapeutics, and molecular targets; and was organized primarily around eight plenary sessions. This made it possible for the entire group of conference participants to hear and discuss the scientific information being presented. Educational Sessions and Concurrent Sessions enabled participants to hear more in-depth discussion of highly focused scientific topics.
Carlos L. Arteaga of Vanderbilt University and Napoleone Ferrara of Genentech delivered Keynote Addresses on Tuesday, November 15. Dr. Arteaga discussed “TGF-β: From Oncogene to Tumor Suppressor to Therapeutic Target in Human Neoplasia.” Dr. Ferrara’s presentation focused on “Discovery and Development of Avastin.” Andrew C. von Eschenbach, Acting Commissioner of the Food and Drug Administration, delivered an address on Monday, November 14, titled “Science with a Purpose.”
The 2005 Molecular Targets and Cancer Therapeutics conference drew over 3,000 participants from 35 different countries representing industry, academia, and government institutions. In addition to the 8 Plenary Sessions and Special Presentations above, the program featured 3 Poster Sessions (over 800 abstracts presented) 3 Proffered Paper Sessions, 2 Educational Sessions, and 8 Concurrent Sessions.